Amgen, a world leader in biotechnology, has been exploring the power of scientific innovation to decisively improve patient’s lives for 30 years.
Amgen is on the cutting edge of developing original products based on recombinant DNA technology and molecular biology, having launched the first revolutionary biotechnology drugs. Today, Amgen is on the Fortune 500 list, helps millions of patients in the fight against serious diseases and continues to be true to its principles based on science.
BIOCANT is a CLUSTER of companies and R&D institutions of excellence with a strong commitment to science education and entrepreneurship.
A unique ecosystem that covers the entire INNOVATION PIPELINE, from the knowledge generation and human resources training to the market, including tech transfer, financing, scientific dissemination and industrial production.
It gathers 30% of the total national number of BIOTECH COMPANIES and provides a wide variety of services and opportunities to develop a competitive business.
Biotrend is a research-based company focused on the development, optimization, de-risking, integration and scale-up of bioprocesses for the production of bio-based chemicals, materials and fuels from renewable raw materials, including complex industrial by-products and wastes. We offer contract research and development services and develop new technologies to be licensed out to industrial clients. We actively participate in international collaborative projects encompassing the full bioeconomy value chain, keeping Biotrend at the forefront of scientific development.www.biotrend.biz
Blueclinical is a translational medicine and clinical research company dedicated to developing medication, medical devices and other healthcare products. Boasting unique skills and experience in the Portuguese market, Blueclinical is the right partner for scientific institutions and companies that are committed to translational medicine projects or to conducting clinical trials on healthy volunteers or patients.www.blueclinical.com
BSIM² is at the forefront of computing technologies to discover the drugs of the future.
Streamlining drug discovery through:
/ Structural Bioinformatics,
/ Network and Systems Pharmacology,
and cutting-edge hardware.
Integrating all discovery stages with Academia and CROs, for:
/ Chemical synthesis,
/ In vitro and in vivo proof-of-concept,
/ Pharmaceutical development.
Making drug candidates against neurodegenerative diseases, steered for:
/ High efficacy,
/ Higher safety,
/ Optimal properties for long-term therapies.
The mission of Coimbra Genomics is to bring individualized medicine to the work environment of every physician. It has therefore developed ELSIE, a genome-based decision-making platform that allows the connection between genome knowledge and clinical practice, helping facilitate the making of important clinical decisions, adapted to the genetic characteristics of each user during normal visits to the doctor. ELSIE is being used on a pilot basis in several countries and began to be used clinically in Germany in 2016.www.coimbra-genomics.com
GenIbet is a biopharmaceutical CMO offering highly specialized Microbial, Cell Culture and Viral Process Development and cGMP manufacturing services to research groups, biotech and pharma companies. This, combined with in-house fill and finish capabilities, gives our clients the opportunity to go from bench to clinic in one facility.
GenIbet’s core activity is the manufacture and supply of materials for use in early stage drug development, pre-clinical studies and cGMP manufacturing from Phase I to Phase III clinical trials.
Bacterial sepsis is responsible for the death of 1.35 million Babies, stillbirths and 1-month old, every year. In addition, preterm birth and morbidity caused by bacterial infections represent an annual cost of nearly US$ 12B a year in the US alone. This is currently an unmet medical need as there is no treatment (pre-infection) able to prevent bacterial infections in fetus and newborns and thus prevent stillbirths and preterm births. Our neonatal vaccine, administered to women, induces the production of protective antibodies in the mother that will be transferred to the fetus protecting the fetus and newborn from bacterial infections. Pre-clinical trials in a mice model of infection showed over 80% survival rate in neonates from immunized mothers, contrasting with the absence of those from non-immunized mothers.www.immunethep.com
We’re more than 30,000 people working hard to prevent, treat, cure and stop some of the most devastating and complex diseases of our time. From heart disease to HIV, Alzheimer’s disease to cancer, we are committed to issues that touch everyone’s lives.http://www.janssen.com/pt
Luzitin is a privately owned pharmaceutical company, focused on the development of photosensitizer compounds for Photodynamic Therapy (PDT).
Founded in 2010, after five years of research collaboration between Bluepharma, the University of Coimbra and the Hospitals of the University of Coimbra, Luzitin is developing a novel and very promising therapeutic procedure for solid tumors (LUZ11) and Acne (LUZACNE). Its proprietary technology consists of a combination of new generation photosensitizer with a specific infrared-laser medical device.
NANO4 Global aims to provide solutions for one step molecular identification of DNA/RNA at point-of-care (PoC). NANO4 Global spins around an awarded platform — NANO4 – the next generation of molecular nanodiagnostics applied to lifesciences.www.nano4global.com
Ophiomics was born from a collaboration between scientists with clinicians sharing the purpose of bringing the latest advances in genomics, bioinformatics and clinical research in support of a Precision Oncology. Ophiomics develops and offers advanced genetic and genomic tests in support of diagnostic, prognostic, pharmacogenomics and clinical follow up. We process both FFPE and Liquid Biospies (based on circulating cell free DNA) to characterise mutational landscapes of tumours, providing guidance for therapy and non-invasive assessments of response to treatment. We offer clinical testing to cancer centres alongside a strong emphasis in clinically-oriented research.www.ophiomics.com
SilicoLife develops state-of-the-art optimization algorithms and uses proprietary computational and modelling tools to accelerate the design of microbial strains, based on metabolic engineering and synthetic biology approaches, shortening the development time and costs of new highly effective processes for the production of specific target compounds such as biofuels, chemicals, food ingredients or biopolymers.www.silicolife.com
Stemmatters is an ambitious regenerative medicine company developing game changing medical devices and combination products for large unmet medical needs.
Research and development centres on unique medical device development platforms, which offer excellent scope for tailoring biological and physicochemical performance for breakthrough applications in regenerative medicine. Fully integrated with specialized and resourceful competences in research and development, Stemmatters additionally offers unique manufacturing competences in regenerative medicine products for external entities.
TechnoPhage is an innovative biopharmaceutical company engaged in the R&D of new molecules – chemical and biological – in diverse therapeutic areas, such as infection, inflammation & immunology, neurology and metabolic disorders. TechnoPhage’s strategy is based on developing new therapeutics in early phases of R&D, with a view to then enter into collaboration deals for pre-clinical and/or clinical development.
Close proximity to the renowned Santa Maria Hospital and the IMM facilitate the creation of multidisciplinary teams with high scientific excellence, essential to the process of translational medicine. Furthermore, this proximity allows direct collaboration with leading experts from various clinical areas where the company is focused, and also facilitates access to the equipment necessary to develop new pharmaceuticals.
TREAT U is developing more effective and safer products for cancer patients by increasing therapeutic efficacy and reducing adverse side effects, hence reducing treatment costs for healthcare systems.
Our first product – PEGASEMP™ – is a proprietary nanotechnology-based delivery platform with application in diagnostics and therapy. PEGASEMP™ targets specifically the tumor microenvironment with triggered delivery of the payload, creating new opportunities in personalized medicine and new value to the Pharmaceutical Market.